Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial

Sadeleştirilmiş öğe sayfası
dc.contributor.authorDincer, Neris
dc.contributor.authorUgurluer, Gamze
dc.contributor.authorOzyar, Enis
dc.date.accessioned2025-10-16T15:16:32Z
dc.date.issued2023
dc.identifier.doi10.1001/jamaoncol.2022.6141
dc.identifier.otherWOS:000914628300003
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/6725
dc.publisherAMER MEDICAL ASSOC
dc.sourceJAMA ONCOLOGY
dc.titleNeoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial
dc.typeLetter

Dosyalar

Koleksiyonlar

WOS